您要查找的是不是：
- The debate here is probably ADH or ductal carcinoma in situ (DCIS). 這里爭論的焦點(diǎn)是ADH還是導管原位癌。
- Objective To study the clinical outcome of breast conserving treatment of breast ductal carcinoma in situ (DCIS). 摘要目的探討乳腺導管內原位癌(DCIS)的保乳術(shù)臨床效果。
- Objective To evaluate the value of ultrasound in diagnosing ductal carcinoma in situ (DCIS). 目的探討乳腺導管內癌的超聲診斷價(jià)值。
- These lesions included ductal carcinoma in situ (DCIS), inasie lobular cancer, cysts, and fibroadenomas. 病變包括乳腺導管原位癌，侵襲性小葉癌，囊腫，纖維腺瘤。
- Objective To study radiologic (molybdenum target X-ray) findings of ductal carcinoma in situ (DCIS) of breast. 目的探討乳腺導管原位癌的鉬靶X線(xiàn)征象。
- Objective:To evaluate the diagnostic value and treatment of intraductal papilloma and ductal carcinoma in situ(DCIS) by Mammoscopy. 目的:探討乳管內視鏡對導管內乳頭狀瘤和導管內癌的診斷價(jià)值和處理的指導意義。
- Abstract: Objective:To evaluate the diagnostic value and treatment of intraductal papilloma and ductal carcinoma in situ(DCIS) by Mammoscopy. 文摘:目的:探討乳管內視鏡對導管內乳頭狀瘤和導管內癌的診斷價(jià)值和處理的指導意義。
- But while three-quarters of these were invasive cancers - the most dangerous type - around 20% were ductal carcinoma in situ (DCIS), more than half of which never become invasive. 然而即便其中四分之三為危害性最大的浸潤性癌，依然有20%25的案例為原位乳腺管癌。半數以上的原位乳腺管癌不會(huì )發(fā)展為浸潤性癌癥。
- Methods In 64 cases of IDC,15 cases of ductal carcinoma in situ(DCIS),15 cases of benign breast tissue and 15 cases of adjacent normal breast tissues,the expression of p57KIP2 proteins was detected by immunohistochemical S-P methods. 方法采用免疫組織化學(xué)S-P法檢測64例IDC、15例乳腺導管內癌(ductal carcinoma in situ,DCIS)、15例乳腺良性病變和15例癌旁正常乳腺組織中p57KIP2蛋白的表達。
- Methods The expression of CD147,MMP-9 and p-ERK was immunohistochemically examined in 96 cases of IDC of breast,34 cases of ductal carcinoma in situ(DCIS) and 10 cases of breast adenosis. 方法應用免疫組化EnvisionTM二步法檢測96例乳腺浸潤性導管癌(invasive ductal carcinoma,IDC)、34例導管內癌(ductal carcinoma in situ,DCIS)及10例乳腺腺病中CD147、MMP-9及p-ERK蛋白的表達,并分析其與臨床病理參數的相關(guān)性。
- The large cells infiltrating into the epidermis represent intraepithelial extension of an underlying ductal carcinoma in situ or invasive ductal carcinoma. 浸潤至真皮的大細胞說(shuō)明位于下方的導管原位癌或浸潤性導管癌向上皮內侵犯。
- Among the 12 suspected cases,2 cases were found with duct carcinoma,2 cases with lobule carcinoma in situ,7 cases with fibroadenoma and 1 case with hyperplasia of mammary glands. 結果12名可疑病例中,經(jīng)手術(shù)和病理證實(shí),乳腺浸潤性導管癌2例,小葉原位癌2例,纖維瘤7例,乳腺增生1例。收藏指正
- However, the positive rates of GCDFP-15 expression in bot h the du ctal carcinoma in situ (81%) and the surrounding normal lobules (71.6%) were si gni ficantly higher than that in invasive ductal carcinoma (P<0.01 and P<0 .001). 導管原位癌表達率 81%25 ;明顯高于浸潤性癌 (P <0 0 1)。 周?chē)Ｈ橄傩∪~表達率為 71 6%25 ;明顯高于浸潤性癌 (P <0 0 1)。
- The expression level of AMF or AMFR in invasive ductal carcinomas was higher than that in ductal carcinomas in situ( P <0.05). 浸潤性導管癌AMF、AMFR水平明顯高于導管內癌 (P =0 .;0 0 1)。
- Keywords Ductal carcinoma in situ;Ultrasound; 關(guān)鍵詞乳腺導管內癌;超聲;
- ductal carcinoma in situ(DCIS) 導管原位癌
- Lobular carcinoma in situ is seen here. 圖示小葉原位癌。
- Value of ultrasound in diagnosing ductal carcinoma in situ 超聲診斷乳腺導管內癌的價(jià)值探討
- Diagnosis and Treatment of Ductal Carcinoma in Situ (A report of 41 cases) 乳腺導管內癌的診斷與處理(附41例報告)
- The Advances of the Diagnosis and Treatment of Ductal Carcinoma in Situ 乳腺導管原位癌診斷和治療的研究進(jìn)展
